The outcome of sibling and unrelated donor allogeneic atem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 3, 2006, Pages 293-300

  Cook, Gordon ^a   Clark, Richard E ^b   Crawley, Charles ^c   Mackinnon, Stephen ^d   Russell, Nigel ^e   Thomson, Kirsty ^f   Pearce, Rachel M ^g   Towlson, Keiren ^h   Marks, David I ^i,j  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^g BSBMT   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^j BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

more..

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; First induction chemotherapy refractory; Sibling donor; Unrelated donor

Indexed keywords

AMSACRINE; ANTIFUNGAL AGENT; ANTILEUKEMIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; TIOGUANINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOGENETICS; DEATH; DONOR; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYCOSIS; PROGNOSIS; RECTUM CANCER; SECOND CANCER; SIBLING; TREATMENT FAILURE; TREATMENT OUTCOME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LIVING DONORS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; WHOLE-BODY IRRADIATION;

EID: 33244477404     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.10.019     Document Type: Article

References (16)

1. R.R. Zittoun F. Mandelli R. Willemze et. al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myeloid leukemia N Engl J Med. 332 1995 217-223
2. S. Suciu F. Mandelli T. de Witte et. al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1) an intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial Blood 102 2003 1232-1240
3. M.L. Slovak K.J. Kopecky P.A. Cassileth et. al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 2000 4075-4083
4. A.K. Burnett K. Wheatley A.H. Goldstone et. al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse results of the UK MRC AML 10 trial Br J Haematol. 118 2002 385-400
5. K. Wheatley A.K. Burnett A.H. Goldstone et. al. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial Br J Haematol. 107 1999 69-79
6. P.D. Kottaridis R.E. Gale M.E. Frew et. al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752-1759
7. R Development Core Team R A Language and Environment for Statiscal Computing Vienna, Austria: R Foundation for Statiscal Computing 2005
8. E.D. Thomas C.D. Buckner M. Banaji et. al. One hundred patients with acute leukaemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation Blood 49 1977 511-533
9. F. Frassoni Randomised studies in acute myeloid leukaemia the double truth Bone Marrow Transplant. 25 2000 471-473
10. E. Papadopoulos M.H. Carabasi H. Castro-Malaspina et. al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia freedom from relapse in the absence of graft-versus-host disease Blood 91 1998 1083-1090
11. D.I. Marks J.M. Bird L. Hunt et. al. T-cell depleted unrelated donor bone marrow transplantation for acute myeloid leukemia Biol Blood Marrow Transplant. 6 2000 646-653
12. J. Sierra J. Bjerke J. Hansen et. al. Marrow transplants from unrelated donors as treatment for acute leukemia Leuk Lymphoma. 39 2000 495-507
13. S. Neudorf J. Sanders N. Kobrinsky et. al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival Blood 103 2004 3655-3361
14. M.S. Tallman D.G. Gilliland J.M. Rowe Drug therapy of acute myeloid leukemia Blood 2005
15. M. De Lima A. Anagnostopoulos M. Munsell et. al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865-872
16. R. Martino M.D. Caballero J.A. Simon et. al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes Blood 100 2002 2243-2245